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Abstract
Background: The rates of oropharyngeal cancers such as tonsil cancers are increasing. The tumour suppressor
protein Programmed Cell Death Protein 4 (PDCD4) has been implicated in the development of various human
cancers and small RNAs such as microRNAs (miRNAs) can regulate its expression. However the exact regulation of
PDCD4 by multiple miRNAs in oropharyngeal squamous cell carcinoma (SCC) is not well understood.
Results: Using two independent oropharyngeal SCC cohorts with a focus on the tonsillar region, we identified a
miRNA profile differentiating SCC tissue from normal. Both miR-21 and miR-499 were highly expressed in tonsil SCC
tissues displaying a loss of PDCD4. Interestingly, expression of the miRNA machinery, Dicer1, Drosha, DDX5 (Dead
Box Helicase 5) and DGCR8 (DiGeorge Syndrome Critical Region Gene 8) were all elevated by greater than 2 fold in
the tonsil SCC tissue. The 3’UTR of PDCD4 contains three binding-sites for miR-499 and one for miR-21. Using a
wild-type and truncated 3’UTR of PDCD4, we demonstrated that the initial suppression of PDCD4 was mediated by
miR-21 whilst sustained suppression was mediated by miR-499. Moreover the single miR-21 site was able to elicit
the same magnitude of suppression as the three miR-499 sites.
Conclusion: This study describes the regulation of PDCD4 specifically in tonsil SCC by miR-499 and miR-21 and has
documented the loss of PDCD4 in tonsil SCCs. These findings highlight the complex interplay between miRNAs and
tumour suppressor gene regulation and suggest that PDCD4 loss may be an important step in tonsillar
carcinogenesis.
Background
Cancers of the head and neck region commonly arise
from the mucosal surfaces of the oral cavity, larynx and
oropharynx. The incidence of head and neck squamous
cell carcinoma (HNSCC) has increased gradually over
the last 3 decades [1]. HNSCC is one of the top six ma-
lignancies affecting men worldwide [1] and the 6th lead-
ing cause of cancer mortality globally [2]; it is estimated
that 500,000 new cases will arise this year. Despite
improvements in clinical care, survival rates of approxi-
mately 50 % have remained unchanged for the past
several decades [1]. According to the most recent NCI
SEER database (http://seer.cancer.gov/faststats/selections.
php?#Output), incidence rates for oropharynx and tonsil
cancers have been increasing since the year 2000. Given
these trends, we still have a limited understanding of
molecular pathways which control the development of
oropharyngeal SCCs, although the human papillomavirus is
a known risk factor for tonsil cancers [3]. Gene array
studies have identified potential cellular candidates for
biomarkers, oncogenes and tumor suppressors [4, 5].
MicroRNAs regulate genes at the post-transcriptional
level by binding to the target 3’ untranslated region
(UTR) and promoting target gene cleavage or transla-
tional inhibition [6, 7]. These small RNAs are frequently
deregulated in human malignancies such as the breast,
lung, colon, and liver [8] and play a major role in
tumorigenesis. Profiling studies of HNSCC cell lines [9]
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miRNA expression. One of the key miRNAs frequently
upregulated in human cancers, including HNSCCs, is
miR-21 [10]. This miRNA [12] and others (for example
miR-150 [13], miR-182 [14]) target the tumor suppressor
programmed cell death protein 4 (PDCD4), which has
been implicated in the development and progression of
several human cancers [15]. Given the numerous
miRNA-binding sites on the 3’UTR of PDCD4, it is
likely that regulation is mediated by multiple miRNAs.
Our study shows a unique focus on tonsillar-derived
miRNAs and investigates the possible regulation of
PDCD4 by multiple miRNAs.
Methods
Patient cohort
The cohort consisted of 43 patients (39 males, 4 females)
treated for tonsillar cancer at Royal Prince Alfred
Hospital Sydney, Australia between 2002 and 2006. The
mean age was 57 years (range 39–80). Seventeen SCCs
and matched microscopically normal adjacent (2 cm
outside the surgical margin) tissues proved suitable for
the profiling analyses. Fixed paraffin-embedded cancers
from 36 of the 43 patients including the 17 used in pro-
filing studies were used for PDCD4 immunohistochem-
istry (Additional file 2: Table S2). Investigations were
approved by the Research Ethics Committee at Royal
Prince Alfred Hospital, Sydney, Australia (Protocols
X05-269, X05-270). This protocol covered consent and
collection of material excess to diagnostic requirements
for research purposes only. A second independent co-
hort sourced from the UK (n=18, 14 males, 4 females)
had a median age of 63 (range 42–92,) was used for fur-
ther miRNA validation. All UK patients gave written in-
formed consent in accordance with the Helsinki
Declaration of 1975, revised 2000. Ethical approval was
obtained from the local institutional Research Ethics
Boards ethics (approval #09/H0606/5, Oxford and South
Manchester).
Cell line culture and transfection
HNSCC cell lines used in this study included SCC089
[16], SCC003 (tonsil) [16], SCC099 (floor of mouth) [16]
and SCC029b (oral cavity) [17] were kindly provided by
Dr. Guy Lyons (Sydney Cancer Centre, Royal Prince
Alfred Hospital, Australia). All HNSCC cell lines were
HPV16 negative. HEK-293 cells were purchased from
ATCC (USA). All cell lines were maintained in DMEM
medium with 1 % L-glutamine (JRH Biosciences, USA)
supplemented with 10 % fetal bovine serum (JRH Bios-
ciencesTM, USA), and 100 mg/L penicillin/streptomycin
(Life Technologies, USA) at 37 °C. Transfections were
performed using Lipofectamine RNAiMAX (Life Tech-
nologies, USA) in triplicate and in 6-well plates. TheLocked Nucleic Acid (LNA) miR-21 antisense and LNA
negative control (Exiqon, Denmark), pre-miR-21, pre-miR-
499 and pre-miR-negative control#1 (Life Technologies,
USA) were separately or double transfected into 2.5 x 105
cells per well to a final concentration of 30 pmol per well.
For PDCD4, 100 ng of the vector was transfected in com-
bination with the miRNAs at 30 pmol per well. Cells from
replicate wells were combined, harvested and divided into
two equal parts and stored at–70 °C until subsequent RNA
and protein analysis. Transfection efficiency was deter-
mined by measuring the relative expression level of the
miRNA using Quantitative Real Time-Polymerase Chain
Reaction (QRT-PCR).
Isolation of RNA from fresh tissue or cultured cells
Approximately 100 mg of fresh frozen tissue was diced
homogenized and then rinsed with 1 ml of Trizol re-
agent (Invitrogen, USA). For the cell lines (SCC089,
SCC003 and HEK-293), 1 ml of Trizol was added to the
cell pellet with further disruption through a 21-gauge
needle. Total RNA was then extracted using isopropanol
precipitation and quantified using a NanoDrop ND 1000
(Thermo Fisher Scientific, USA). Samples with ratios of
260/280 in the range of 1.71 to 2.1 were used for the
downstream studies.
Total RNA labeling
MicroRNAs were labeled at 3’-end with a P-CU-C3-Cy3
RNA linker by RNA ligation as described [18]. A 60 μL
ligation reaction was prepared with 6 μg of total RNA,
0.1 mM ATP, 20 mM MgCl2, 3.5 mM DTT, 10 mg/ml
BSA, 10 % DMSO, 50 mM HEPES, pH 7.8, 250 ng of P-
CU-C3-Cy3 (GeneLink, USA) and 20 units of T4 RNA
ligase (NEB, USA). The reaction was incubated on ice
for 2 h followed by precipitation at–70 °C for 20 min
with 0.3 M sodium acetate, 0.5 mg/ml glycogen (Life
Technologies, USA) and 2 volumes of 100 % ethanol to
remove any unbound RNA-linkers. Each labeled sample
was dissolved in 30 μl of 400-fold diluted ULS labeled
reference set, then mixed with 300 μl Church and
Gilbert hybridization buffer. This mixture was denatured
at 95 °C for 2 min before hybridization. A mixture of 371
synthetic DNA reference oligonucleotides (Sigma-Genosys,
Australia) containing complementary sequences to all
LNA probes, was randomly labeled using the ULYSIS
labeling kit (Invitrogen, USA) and then filtered using a
MicroSpinTM G-25 column (Amersham, USA). Aliquots
of a 400-fold dilution of labeled reference set were stored
at–20 °C until needed.
Microarrays
A commercial LNA-modified oligonucleotides library
(Exiqon, Denmark) based on miRBase release 7.1, cover-
ing 371 human and mouse miRNA was utilized for
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II slides (Amersham, USA) at a concentration of 10 μM
(Australian Genome Research Facility, Australia).
Individual miRNA LNA probes were printed four times
on each array. In addition, all samples were arrayed in
technical duplicate. Pre-hybridization of array slide was
performed in 3x SSC, 0.1 % SDS, 0.2 % BSA at 60 °C for
1 h. Each slide was then rinsed with in full DEPC treated
water, followed by 100 % ethanol. Hybridization was
then performed in disposable reaction chambers
(ABGene, USA). The combined hybridization mixture
of 330 μl was injected into the chamber, and then
incubated in a hybridization oven with constant
rotation at 5 rpm for 3 h at 52 °C. Slides were then
washed briefly in 4x SSC, twice in 2x SSC plus 0.1 %
SDS, twice in 0.2 % SSC and twice in 0.1 % SSC.
These were then scanned with a Genepix 4000B
Scanner (Axon Instruments, USA).
Microarray data analysis
Raw data manipulation and downstream statistical ana-
lyses were performed using the TM4 suite (http://
www.tm4.org) [19]. Normalization included Lowes cor-
rection followed by in-slide replicate analysis. The data
were then filtered by a percentage cut-off of 95 % and
then subjected to statistical data mining. Two-class un-
paired hierarchical clustering (HCL) of samples was con-
structed with average linkage and Pearson correlation. Dif-
ferential miRNA expression was then analyzed by
Significance Analysis of Microarrays (SAM). A list of sig-
nificantly expressed miRNA genes was generated with a
false discovery rate (FDR) of 0. The data discussed in this
publication have been deposited in NCBI's Gene Expres-
sion Omnibus [20] and are accessible through GEO Series
accession number GSE75630 (http://www.ncbi.nlm.nih.-
gov/geo/query/acc.cgi?acc=GSE75630).
Reverse transcription quantitative real-time PCR
(QRT-PCR)
QRT-PCR setup and analysis were performed using the
MIQE guidelines [21]. In brief, total RNAs were treated
with RNase-free DNaseI (Promega, Australia). Measure-
ment of individual miRNAs or genes was determined
using a two-step QRT-PCR approach. cDNA was firstly
generated using the Hi-capacity cDNA Reverse Transcrip-
tion Kit (Life Technologies, USA). For QRT-PCR detec-
tion, we use TaqMan specific kits. The miRNA primers
plus the U75 RNA primer were combined in equal molar
concentrations into 500 ng of total RNA to generate
miRNA cDNA. For genes such as Dicer, random hexam-
ers were added to 500 ng of total RNA. A standard 15 μl
reverse transcription reaction was performed with the end
product diluted 1:4 for the subsequent QRT-PCR. All
QRT-PCR reactions were performed in technical triplicateusing the Universal PCR Master Mix, No AmpErase UNG
(2x) (Life Technologies, USA) and cycled on a 7900 Real-
Time PCR System (Life Technologies, USA). Mean Ct
values were normalized using the nuclear RNA U75 for
miRNA expression or B2M for normal genes. U75 was
used as it represented a stable calibrator, which did not
change between our patient’s samples. Similarly, we uti-
lised B2M as the reference gene for normalisation of
mRNA expression. Relative expression level of a given
miRNA or gene was calculated using DeltaDelta Ct
method and presented as fold change relative to the
control [22].
Cloning of the PDCD4 constructs
The PDCD4 coding sequence and the first 789 bp of the
3’UTR (NM-014456.3) containing the miR-21 and three
miR-499 binding sites were chemically synthesized into
the pJ246 vector (DNA 2.0 Inc, USA) with EcoRI, EagI
sites at the 5’ start of the UTR and NotI at the 3’ end.
The PDCD4 coding region with and without 709 bp
3’UTR fragment was then excised with EcoRI/NotI or
EcoRI/EagI and sub-cloned into the MCS of the pCI-neo
vector (Promega, Australia).
Western blotting
Cells were lysed on ice in buffer containing 50 mM
HEPES (pH 7.5), 150 mM NaCl, 10 % glycerol, 1 mM
EGTA, 10 mM Na pyrophosphate, 100 mM NaF and
1 mM NaVO4. Protein concentration was determined
by using the DC protein assay kit using BSA as a stand-
ard (BioRad, USA). Protein separation was achieved
using 30 μg on the NuPAGE (4-12 %) Bis-Tris Gel
(Invitrogen, USA) and then transferred onto PVDF
membrane (PIERCE, USA). Membranes were blocked
with 5 % skim milk for 1 h and then incubated with
primary anti-PDCD4 rabbit antibody (Sigma-Aldrich,
USA) at a 1: 1000 dilution overnight at 4 °C. The
membrane was then washed with PBS-0.05 % Tween-
20 and conjugated with the secondary IgG-HRP anti-
rabbit (Amersham Biosciences, USA) in 1:10,000 for
1 h. Specific protein signals were detected using the
ECL plus reagent (Amersham Biosciences, USA). Beta-
actin was detected using a rabbit polyclonal at 1:5000
dilution (Abcam, USA) and secondary reaction with a
goat polyclonal anti rabbit IgG, 1:2000 dilution
(Abcam, USA).
Immunohistochemistry
Sections were deparaffinized, rehydrated, antigen retrieved
as previously described [23]. Slides were then incubated
with a 1:300 anti PDCD4 rabbit Ab (Sigma-Aldrich, USA)
for 1 h with subsequent detection using the EnVision +
Dual Link System (Dako, USA). All reactions were con-
ducted on the DAKO Autostainer, Universal Staining
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dependent observers including one pathologist and classi-
fied as: (−) negative staining; low to high positive staining
(+ to +++), and scored as percentage of stained cells [24].
The reduction of PDCD4 staining was determined by com-
parison of the PDCD4 staining between normal epithelial
and tumor tissues in the same section.
Results
Seventeen tonsillar cancers SCCs and matching adjacent
macroscopically normal tissues were subjected to miRNAFig. 1 a Heatmap showing two class-SAM analyses for differentially expres
samples. miRNA genes shown in yellow and blue represent up-regulated a
miR-21 and let7c in the Australian patient cohort (n = 10). Each miRNA was
paired normal tissue. c Validation of let-7c, miR-21 and miR-499 was perfor
biogenesis machinery in 10 paired tonsil SCC samples. Expression of each g
paired normal tissueexpression profiling. The data were mined using unsuper-
vised hierarchical clustering (HCL) and principal compo-
nent analysis (PCA) (Additional file 1: Figure S1). This
indicated that tonsillar cancers had a distinct miRNA pro-
file when compared to normal tissue and this signature
was able to cluster samples in either a tumor or normal
group. We identified differentially expressed miRNAs
using the statistical analysis of microarrays (SAM) algo-
rithm [25] (Fig. 1a). When we applied SAM analysis to in-
clude a 2-fold cut off, miR-350 was eliminated. In
contrast, the eleven other miRNAs showed a 2-foldsed miRNAs in tonsil cancers. Green bar: normal samples, red bar: SCC
nd down-regulated, respectively. b Validation of miR-372, miR-499,
determined in the tumor tissue with fold expression normalized to
med using a second UK patient cohort. d Expression of the miRNA
ene was determined in the tumor tissue and then normalized to the
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expressed miRNAs, nine of which were upregulated while
two miRNAs were downregulated in cancers relative to
normal tissue (Table 1). Some of the upregulated miRNAs
included, miR-499, miR-372, miR-18a, miR-21 and miR-
30d, while let-7c and miR-198 were downregulated.
The array data were then confirmed by QRT-PCR of 4
representative miRNAs using ten tumour and adjacent
normal samples. This indicated a strong concordance
between the two data sets (Fig. 1b). Given that most of
the miRNAs were upregulated, we also measured the ex-
pression of the biogenesis machinery using QRT-PCR.
The analysis of ten tonsil SCC with paired normal tissue
showed that Dicer1, Drosha, DDX5 and the DiGeorge
critical region gene (DGCR8) were all upregulated by
greater than two-fold relative to normal tissue (Fig. 1d).
The expression levels of miR-21 and miR-499 are known
to control the translation of the tumour suppressor
PDCD4 and let-7 has been shown to regulate Dicer
levels. Given the importance of these miRNAs we fur-
ther confirmed their expression using an independent
cohort of tonsillar specimens sourced from the UK
(n=−22 tonsillar cancers and matched normal tissues)
(Fig. 1c).
The 3’ UTR of PDCD4 contains three binding sites
for miR-499 and one for miR-21 (Additional file 1:
Figure S2). In tonsillar SCCs samples, both miR-21 and
miR-499 were elevated but the RNA levels for PDCD4
was markedly lower (Fig. 2a). Furthermore, 30 of the 36
tonsil cancers examined by semi quantitative immuno-
histochemistry showed reduced expression of PDCD4
in tumour cells relative to the surrounding normalTable 1 (A) List of deregulated miRNAs identified in tonsillar
cancers. These miRNAs demonstrate a two-fold change from
normal tonsillar tissue. (B) ΔΔG free energy value, which can be
used to evaluate target site accessibility. This value was determine
using the PITA algorithm (http://genie.weizmann.ac.il/pubs/mir07/












miR-198 0.40epithelial cells (Fig. 2b and c and Additional file 2:
Table S2).
Four HNSCC cancer cell lines (SCC029b, SCC003,
SCC099, SCC089) were screened by QRT-PCR to deter-
mine the relationship between miR-21 and PDCD4 ex-
pression (Additional file 1: Figure S3). In all the HNSCC
cell lines, there was an inverse relationship between the
levels of miR-21 and PDCD4 expression. Given SCC089
cells showed high endogenous levels of miR-21 and
could be easily transfected, we delivered a LNA anti-
sense to regulate expression of miR-21. At 48 h and 72 h
post transfection, miR-21 levels were reduced by greater
than two-fold (Fig. 2d). The reduction in miR-21 was
marked by a large increase in PDCD4 mRNA and pro-
tein expression at 48 h in SCC089 cells (Fig. 2e and f
respectively). In addition, the LNA antisense control
showed no effect on PDCD4 expression in either control
HEK-293 cells or SCC089 cells. This effect was also
confirmed using another independent HNSCC cell line
(SCC003- Additional file 1: Figure S4). Therefore the
reduction of miR-21 levels in tonsillar cancer cell lines
was marked by an increase in PDCD4 expression.
To investigate whether miR-21 and miR-499 directly
interact with the 3’UTR of PDCD4, the open reading
frame (ORF) of PDCD4 with and without a 789 bp sec-
tion of its 3’UTR which contained the miR-21 and miR-
499 sites was cloned into the pCI-neo expression vector
(Fig. 3a). Given SCC089 cells showed low endogenous
levels of PDCD4, these cells were transiently transfected
to overexpress PDCD4 with and without the 3’UTR in
combination with miR-21 or miR-499. We observed no
downregulation of PDCD4 lacking its 3’UTR. In con-
trast, when the 3’UTR was included, PDCD4 mRNA
expression was significantly reduced by miR-21 and
miR-499 (Fig. 3b). Similarly, PDCD4 protein expression
was significantly downregulated only in cells with the
PDCD4 3’UTR (Fig. 3c). We also transiently transfected
SCC003 cells with PDCD4 with and without the 3’UTR,
and as expected, PDCD4 mRNA expression was down-
regulated by both miR-21 and miR-499 only when the
3’UTR was present (Additional file 1: Figure S5).
The PDCD4 3’UTR has over 31 broadly conserved
miRNA sites. Thus, it may be plausible that both miR-21
and miR-499 can regulate PDCD4. Using the HEK-293-
cell line, which expresses stable levels of PDCD4, we
transfected, miR-21/miR-499 alone or in combination
and levels of PDCD4 were measured over a 96 h time
period. Cells overexpressing miR-21 showed a reduction
in PDCD4 mRNA and protein at only 24 and 48 h and
not the later time points (Fig. 4a and b). In contrast,
miR-499 had no affect at 24 h with suppression of
PDCD4 only seen at 48 h and being sustained for the
duration of the time course. As expected, cells contain-
ing both miRNAs demonstrated reduced expression of
Fig. 2 a Expression levels of PDCD4, miR-21 and miR-499 in tonsil SCC tissue normalized to expression in adjacent healthy tissue (10 patients
were analyzed in this cohort). b Panel i) Representative staining of PDCD4 in normal epithelium with a 3+ scoring intensity. Panel ii) PDCD4
staining in Tonsil SCC tissue with a 3+ scoring intensity. Panel iii) PDCD4 staining in Tonsil SCC tissue with a 2+ scoring intensity. Panel iv)
negative PDCD4 staining in Tonsil SCC tissue. c Summary of PDCD4 expression in tonsil cohort (+ to +++, with three + being high expression).
d Reduction of miR-21 levels using a LNA anti-sense in SCC089 cell lines. Expression of miR-21 was then normalized to the LNA antisense scramble
control. e PDCD4 mRNA levels in miR-21 depleted cells normalized against the LNA antisense scramble control. f Protein Expression of PDCD4 in
miR-21 depleted SCC089 and HEK-293 cells














































































































































































































































































Fig. 3 a Schematic representation of the PDCD4 constructs with
and without the 3’UTR. b mRNA expression of PDCD4 in SCC089
cells transfected with PDCD4 constructs with and without the 3’UTR.
These cells were also co-transfected with either miR-21, miR-499
alone or in combination and harvested 24 h post transfection.
PDCD4 levels were only normalized to the reference gene B2M and
fold change calculated using DeltaDelta Ct method. c Protein
expression of PDCD4 in the co-transfected cell described in (B).
PDCD4 expression was then quantitated relative to Beta-actin levels
Zhang et al. BMC Cancer  (2016) 16:86 Page 7 of 11PDCD4 throughout the entire time course. Furthermore,
we measured the expression of the transfected miRNAs
and this indicated consistent high expression of both
miR-21 and miR-499 at all-time points (Additional file 1:
Figure S6A and B). The exact conditions were then
tested in the SCC003 tonsillar cells with similar findings
(Additional file 1: Figure S6C). Taken together these ob-
servations suggest that miR-21 and miR-499 can both
regulate the expression of PDCD4.
Discussion
Our study identified eleven differentially expressed miR-
NAs in a series of tonsillar cancers, nine of which
showed greater than a two-fold change. In line with pre-
vious reports of head and neck cancer [10, 11, 26–34]
miR-499, miR-372, miR-18a and miR-21 were upregu-
lated in our series. The upregulation of miR-30d seems
unique to our analysis. The downregulation of let-7c and
miR-198 is supported by other recent findings [10, 28].
Several of these miRNAs were validated using an
Australian and UK tonsillar SCC cohorts further sup-
porting their clinical expression. That is, the miRNAs
expression is robust and display similar expression levels
in different tonsil SCC patients.
As the majority of miRNAs were elevated compared to
normal tissue, this may suggest an alteration in the
miRNA biogenesis machinery. Subsequent QRT-PCR
measurement of Drosha, Dicer1, DDX5 and DGCR8 in-
dicated a general overexpression of all four biogenesis
components in tonsillar cancers. These findings may be
linked with the downregulation of let-7, which has been
shown to negatively regulate Dicer1 expression [35]. The
upregulation of Dicer1 in tonsillar cancers is consistent
with studies in salivary pleomorphic adenomas [33] and
oral cancers [36]. These findings may suggest that de-
regulation in the biogenesis machinery is linked to the
deregulation of specific miRNAs in tonsillar cancers. In-
deed this may be a wider phenomenon as other cancers
such as bladder [37], prostate [38] and lung adenocarcin-
omas [39] also demonstrate aberrant expression of either
Dicer1 or Drosha.
To understand the regulatory role of miRNAs in ton-
sillar carcinogenesis we investigated PDCD4 as a target.
PDCD4 is a tumor suppressor [40] and an inhibitor of
protein translation [41]. Little is known about the ex-
pression and regulation of this tumor suppressor in
tonsillar cancers. We show that miR-21 and miR-499
directly interact with the 3’UTR of PDCD4 in both
HEK-293 and tonsil cancer cell lines. The single miR-21
site was able to elicit the same magnitude of suppression
as the three miR-499 sites. There was also no significant
additive suppressive effect in cells overexpressing both
miR-21 and miR-499. Importantly, staining for PDCD4
demonstrated a loss of expression which is similar to the
ab
Fig. 4 a Expression of PDCD4 mRNA in HEK-293 cells overexpressing miR-21 or miR-499 alone or in combination. PDCD4-mRNA fold change
values were expressed relative to control cells containing the Pre-miR control and calculated using the DeltaDelta Ct method for n = 3. b Protein
expression of PDCD4 in the same HEK-293 cells described above. PDCD4 protein expression was reduced by miR-21 at 24 and 48 h but returns
to basal levels by 72 and 96 h. In contrast, miR-499 decreases PDCD4 expression from 48 h thereafter. As expected the combination of both
miRNAs reduce PDCD4 mRNA and protein expression from 24 h
Zhang et al. BMC Cancer  (2016) 16:86 Page 8 of 11profile observed in lung [42], colon [43], prostate [43],
and ovarian cancers [44]. In these cancers, loss of
PDCD4 expression was associated with disease progres-
sion. It is not known whether PDCD4 expression is a
predictor of outcome in tonsil cancer. However reduc-
tion of PDCD4 was marginally associated with nodal
metastasis in oral cancers [45].
Reis et al. showed that PDCD4 is regulated by miR-21
in head and neck cancers [45]. More recently, miR-499was shown to also regulate PDCD4 in colorectal cancer
[46]. Our study has extended these findings by showing
that in tonsillar SCCs, PDCD4 is also regulated by miR-
499 and miR-21. The initial suppression at 24 h ap-
peared to be mediated by miR-21 only. However as the
time course was extended, miR-21 was unable to sup-
press PDCD4. In contrast, miR-499 had no effect ini-
tially but was effective at the 48 h and beyond. The
delay in miR-499 suppression at 24 h cannot be
Zhang et al. BMC Cancer  (2016) 16:86 Page 9 of 11attributed to miR-499 levels, as overexpression of the
mature miR-499 was similar at all-time intervals. Fur-
thermore, expression of the synthetic mature miR-21
was consistent over the 96 h but suppression of PDCD4
was only apparent at 24 h.
This regulation of PDCD4 by miR-499 and miR-21
may be explained by target site accessibility and seed re-
gion constraints. Evidence now indicates that binding
sites 15 nt from the stop codon and sites positioned in
the centre of long UTR’s display reduced silencing ability
[47]. One of the miR-499 sites is located within 13 nt of
the stop codon, whilst the other two are placed closer to
the centre of the UTR. In contrast, the miR-21 site is po-
sitioned outside these accessibility constraints and there-
fore may have the ability to exert a rapid silencing effect.
We calculated site accessibility by determining the ΔΔG
free energy value using the PITA model, Table 2 [48].
The miR-21 site showed a lower free energy value and is
interpreted as being more accessible than the other miR-
499 sites. Furthermore, the seed region of miR-21 is a
8mer match while the miR-499 seed is at best a 7mer-
1A. Considering these factors, we propose that may be
miRISC/miR-21 initially binds to the miR-21 site to rap-
idly mediate PDCD4 gene silencing within 24 h. After
this initial binding, the miRISC/miR-21 may recruit
other factors to expose the downstream miR-499 sites.
These sites would now be accessible to miR-499, which
would maintain the silencing of PDCD4. Although our
model awaits further elucidation it does establish the ex-
citing premise that miR-21 may induce gene repression
by promoting the accessibility of other miRNA sites.
It must also be noted that our tumour samples and
cell lines were HPV16 negative. Thus, the deregulation
of miR-21 and miR-499 was not influenced by the pres-
ence of the virus. However, the study by Ko et al., did re-
port miR-21 up regulation in 30 % of their HPV16
positive tumours [49]. We also conducted a separate
profiling study (unpublished data), which investigated
the miRNA profile between HPV16 positive and HPV16
negative tonsil SCC. We found that miR-21 and miR-Table 2 (A) List of deregulated miRNAs identified in tonsillar
cancers. These miRNAs demonstrate a two-fold change from
normal tonsillar tissue. (B) ΔΔG free energy value, which can be
used to evaluate target site accessibility. This value was determine
using the PITA algorithm (http://genie.weizmann.ac.il/pubs/mir07/
mir07_prediction.html) for the first 789 bp 3’UTR of PDCD4
microRNA Position ΔGduplex ΔGopen ΔG
miR-21 241 −10.8 −8.1 −2.69
miR-499 466 −9.5 −7.91 −1.58
miR-499 532 −17.6 −16.02 −1.57
miR-499 17 −15 −21.04 6.04499 were not up-regulated in HPV16 positive tonsil
SCCs. Interestingly, the cohort of miRNAs were very dif-
ferent and we suggest that, HPV16 may control the ex-
pression of other specific miRNAs and which are not
common to HPV negative tumours.
Conclusions
In summary, this study has characterized the expression
of miRNAs in tonsillar cancers using two independent
patient cohorts. Some of these miRNAs appear to be
unique for tonsillar cancers. This is very pertinent given
the lack of reliable biomarkers for this disease. We have
further shown that the tumor suppressor PDCD4 is lost
in the majority of tonsil SCCs and PDCD4 is directly
regulated by two miRNAs. There appears to be a novel
interplay between miR-499 and miR-21 in the regulation
of PDCD4. Although further studies are needed to dis-
sect this interaction, these results do highlight the com-
plexity of miRNA-target gene regulation and suggest
that PDCD4 loss may be an important step in tonsillar
carcinogenesis.
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